YENISLEIDYS MILAN: Open Payments
NPI 1043755481 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$434 in 14 payments from 10 companies in 2025. Trend: 2023 $318 · 2024 $163 · 2025 $434
Food & beverage: $434
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 1 | $139 |
| Novartis Pharmaceuticals Corporation | 4 | $95 |
| Incyte Corporation | 2 | $49 |
| Daiichi Sankyo Inc. | 1 | $28 |
| TerSera Therapeutics LLC | 1 | $24 |
| Astellas Pharma US Inc | 1 | $24 |
| PFIZER INC. | 1 | $22 |
| AstraZeneca Pharmaceuticals LP | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| RECORDATI_RARE_DISEASES_INC. | 1 | $16 |
Products named: RYBREVANT, PLUVICTO, Enhertu, MONJUVI, Zoladex, Xospata, ELREXFIO, NIKTIMVO.
Industry payments across FL — which companies pay providers there.
